New Delhi: Glenmark Pharmaceuticals Ltd today said its subsidiary has received approval from the US health regulator to sell generic versions of AstraZeneca`s Zomig and Zomig ZMT tablets, a migraine drug, in the American market. Glenmark Generics Inc, a subsidiary of Glenmark, has received approval from US Food and Drug Administration (USFDA) for Zolmitriptan tablets and Zolmitriptan Orally Disintegrating tablets, Glenmark said in a statement. "Glenmark will commence distribution of the product immediately," the Mumbai-based firm said. Zolmitriptan Tablets and Zolmitriptan ODT are indicated for the acute treatment of migraine headaches in adults. According to IMS Health, for the 12-month period ended December 2012, the products garnered annual sales of USD 176 million.
Origin of our hips much simpler than thought
US laud India for developing rotavirus vaccine